Epidermal growth factor receptor tyrosine kinase inhibitors: Present and future role in gastrointestinal cancer treatment: A review

Oncologist

Volumn 11, Issue 6, 2006, Pages 602-611

  Arnold, Dirk ^a   Peinert, Stefan ^a   Voigt, Wieland ^a   Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Colorectal cancer; Epidermal growth factor receptor; Gastroesophageal cancer; Gastrointestinal cancer; Pancreatic cancer; Tyrosine kinase inhibitor

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; OXALIPLATIN; PELITINIB;

ABDOMINAL PAIN; ANOREXIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; ESOPHAGUS CANCER; FATIGUE; FEVER; HUMAN; HYPOKALEMIA; INFECTION; LEUKOPENIA; LUNG CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PARESTHESIA; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SKIN TOXICITY; TASTE DISORDER; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS;

EID: 33745674902     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-6-602     Document Type: Review

References (56)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
2. Cohen MH, Williams GA, Sridhara R et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. The Oncologist 2003;8:303-306.
3. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
4. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
5. Ochs J, Grous JJ, Warner KL. Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a US expanded access programme (EAP). Proc Am Soc Clin Oncol 2004;23:628.
6. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III clinical trial - INTACT 1. J Clin Oncol 2004;22:777-784.
7. Herbst RS, Giaccone G, Schiller J et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-794.
8. Perez-Soler R, Chachoua A, Huberman M et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:310.
9. Shepherd FA, Rodrigues-Pereira J, Ciuleanu TE et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
10. Gatzemeier U, Pluzanska A, Szczesna A et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;22:7010a.
11. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5898.
12. Goss G, Hirte H, Miller WH Jr et al. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 2005;23:147-155.
13. Mackenzie MJ, Hirte HW, Glenwood G et al. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 2005;23:165-170.
14. Rothenberg ML, LaFleur B, Levy DE et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005;23:9265-9274.
15. Oza AM, Townsley CA, Siu LL et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22:196.
16. Niederle N, Freier W, Porschen R et al. Erlotinib as single agent in 2nd and 3rd line treatment in patients with metastatic colorectal cancer. Results of a two-cohort multicenter phase II study. Eur J Cancer 2005;3(suppl 3):184.
17. Fields ALA, Rinaldi DA, Henderson CA et al. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. A phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU in combination with irinotecan and/or oxaliplatin. Proc Am Soc Clin Oncol 2005;23(16 suppl):3583a.
18. Hammond LA, Figueroa J, Schwartzberg L et al. Epidermal growth factor receptor tyrosine kinase inhibitor, ZD1839 ('Iressa'), in combination with 5-fluorouracil and leucovorin, in advanced colorectal cancer. Poster presented at the 11th European Cancer Conference, Lisbon, Portugal, October 21-25, 2001.
19. Bridgewater JA, Harrison M, Broby S et al. Phase I clinical trial of gefitinib and 5FU in patients with 5FU-refractory colorectal cancer. Poster presented at the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, Hollywood, Florida, January 27-29, 2005.
20. Jimeno A, Sevilla I, Gravalos C et al. Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy. Proc Am Soc Clin Oncol 2005;23(16 suppl):3176a.
21. Chau I, Massey A, Higgins L et al. Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine-refractory advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2004;23:263.
22. Veronese ML, Sun W, Giantonio B et al. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer 2005;92:1846-1849.
23. Hochhaus A, Hofheinz R, Heike M et al. Phase I study of gefitinib in combination with FOLFIRI as 2nd-/3rd-line treatment in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2005;23(16 suppl):3674a.
24. Arnold D, Constantin C, Seufferlein T et al. Phase I study of gefitinib in combination with capecitabine and irinotecan for 2nd- and/or 3rd-line treatment in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2005;23(16 suppl):3691a.
25. Casado E, Folprecht L, Paz-Ares L et al. A Phase I/IIA pharmacokinetic and serial skin and tumor pharmacodynamic study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil leucovorin and irinotecan (FOLFIRI regimen) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2004;23:256.
26. Messersmith WA, Laheru DA, Senzer NN et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004;10:6522-6527.
27. Cho CD, Fisher GA, Halsey J et al. A phase II study of IFOX (gefitinib with FOLFOX-4) in patients with unresectable or metastatic colorectal cancer. Poster presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004.
28. Zampino MG. Gefitinib combined with simplified FOLFOX-6 as first-line treatment in epidermal growth factor receptor (EGFR)-positive advanced colorectal cancer. Poster presented at the 29th European Society for Medical Oncology Conference, Vienna, Austria, October 30-November 2, 2004.
29. Kuo T, Cho C, Halsey J et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2005;23:5613-5619.
30. Mosconi S, Cascinu S, Zaniboni A et al. The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial. Tumori 2000;86:465-469.
31. Hartmann JT, Kroening H, Bokemeyer C et al. Phase I study of gefitinib in combination with oxaliplatin and weekly 5-FU/LV (FUFOX) for second-/third-line treatment in patients (pts) with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2005;23:3154a.
32. Hanauske AR, Diaz-Rubio E, Cassidy J et al. Erlotinib HCl in combination with FOLFOX4 in patients with solid tumors. Proc Am Soc Clin Oncol 2003;22:197.
33. Messersmith WA. Phase I trial and biologic study of erlotinib combined with FOLFOX-4 in patients with advanced colorectal cancer: Initial results. Poster presented at the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, Hollywood, Florida, January 27-29, 2005.
34. Tejpar S, Van Cutsem E, Gamelin E et al. Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2004;23:265.
35. Delord J, Beale P, Van Cutsem E et al. A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in colorectal cancer (MCRC) patients. Proc Am Soc Clin Oncol 2004;23:266.
36. Meyerhardt J, Xhu A, Enzinger D et al. Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2004;23:265. Data from poster.
37. Zeuli M, Gelibter A, Nardoni C et al. A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2004;23:306.
38. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002;29(suppl 14):3-9.
39. Song HS, Kim IH, Sohn SS et al. Prognostic significance of p53, Rb, EGFR, and c-erB2 genes in curatively resected gastric cancer. Proc Am Soc Clin Oncol 2003;22:263.
40. Malecka-Panas E, Fligiel SEG, Relan NK et al. Azoxymethane enhances ligand-induced activation of EGF receptor tyrosine kinase in the colonic mucosa of rats. Carcinogenesis 1996;17:233-237.
41. Roberts RB, Min L, Washington MK et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis, Proc Natl Acad Sci U S A 2002;99:1521-1526.
42. Rojo J, Tabernero E, Van Cutsem E et al. Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD 1839). Proc Am Soc Clin Oncol 2003;22:191.
43. Doi T, Koizumi W, Siena S et al. Efficacy, tolerability, and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer [abstract]. Proc Am Soc Clin Oncol 2003;22:258.
44. Radovich D, Kelsen D, Shah M et al. OSI-774 in advanced esophageal cancer: a phase II study. J Clin Oncol 2004;22(suppl):23:331.
45. Van Groeningen C, Richel D, Giaccone G. Gefitinib phase II study in second-line treatment of advance esophageal cancer. Proc Am Soc Clin Oncol 2004;23:318. Data from poster.
46. Ferry DR, Anderson M, Beddows K et al. Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. Proc Am Soc Clin Oncol 2004;23:317.
47. Adelstein DJ, Rybicki LA, Carroll MA et al. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GeJ) cancer. Proc Am Soc Clin Oncol 2005;23(16 suppl):4054a.
48. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Am Soc Clin Oncol 2005;23(16 suppl):1a.
49. Blaszkowsky LS, Kulke KH, Ryan DP et al. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2005;23(16 suppl):4099a.
50. Iannitti D, Dipetrillo T, Barnett JM et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Poster presented at the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, Hollywood, Florida, January 27-29, 2005.
51. Kortmansky JS, O'Reilly EM, Minsky BD et al. A phase I trial of erlotinib, gemcitabine and radiation for patients with locally-advanced, unresectable pancreatic cancer. Poster presented at the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, Hollywood, Florida, January 27-29, 2005.
52. Lenz HJ, Mayer RJ, Gold PJ et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 2004;22(14 suppl):3510a.
53. Berlin J, Malik I, Picus J et al. Panitumumab therapy with irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Ann Oncol 2004;15(suppl 3):iii70.
54. Voigt W, Pickan V, Pfeiffer C et al. Preclinical evaluation of ZD1839® alone or in combination with oxaliplatin® in a panel of human tumor cell lines - implications for clinical use. Onkologie 2005;28:482-488.
55. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
56. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.